Sample issue — this is a real, complete edition of the monthly report Cost Tracker members receive by email, plus a taste of the personalization members get.
GLP-1 cost & coverage report — July 2026
All prices verified on official source pages July 12–13, 2026 · Next full update: early August 2026
Show my situation
1. Which medication?
2. How do you pay?
Your choices stay on your device — nothing is saved or sent.
What changed in July
- Medicare's GLP-1 Bridge is live: $50/month. First-ever Medicare coverage of weight-loss GLP-1s started July 1 — covered products are Foundayo, Wegovy (pen or pill), and Zepbound KwikPen only. Eligibility runs on BMI plus health conditions; see the full rules. See the full rules.
- Massachusetts dropped weight-loss GLP-1s from Medicaid. Effective July 1, about 22,000 MassHealth members lost coverage for weight-loss-only prescriptions; a narrower medical-necessity path remains. Most published "which states cover GLP-1s" lists haven't caught this yet.
- Compounded GLP-1s: FDA's final decision still pending. The proposal to permanently end mass compounding of semaglutide/tirzepatide closed for comments in late June. No final determination as of July 13 — we check twice a week and will alert members the week it lands.
Current prices
| Drug & form | Cash/self-pay | With commercial insurance | Medicare (Bridge) | The catch |
|---|---|---|---|---|
| Wegovy pen | $199/mo intro (first 2 fills, 0.25/0.5mg only, thru Dec 31) → then $349/mo; 7.2mg HD $399/mo | As little as $25/mo (savings card, max benefit $100/mo) | $50/mo | Intro price requires being new to the savings program |
| Wegovy pill | $149/mo (1.5mg and 4mg) | As little as $25/mo | $50/mo | 4mg offer ends Aug 31 → $199/mo |
| Ozempic pen | $199/mo intro (first 2 fills) → $349/mo (0.25–1mg) or $499/mo (2mg) | As little as $25/mo (up to 3-month fills) | — (diabetes coverage via Part D separate) | Intro offer thru Dec 31 |
| Ozempic pill | $149/mo (1.5mg) new patients; $199 (4mg) / $299 (9mg) existing | As little as $25/mo | — | Tier depends on dose and patient status |
| Zepbound (vial or KwikPen) | $299 (2.5mg) / $399 (5mg) / $499 (7.5mg) / $699 (10–15mg) | Single-dose pen from $25/mo (copay card) | $50/mo — KwikPen only | Higher tiers discount to $449 ONLY if you refill within 45 days — miss the window, pay $499–699 |
| Foundayo pill | $149/mo (0.8mg); $199 (2.5mg); $299 (higher doses) | As little as $25/mo (card expires Dec 31, 2026; $1,000 annual cap) | $50/mo | Higher-dose pricing sits in the fine print, not the headline |
| GoodRx route | Wegovy tablets $149/mo; Zepbound $995/mo — avoid | — | — | For Zepbound, GoodRx is ~2–3x Lilly's own direct price right now |
Deadlines to know
| Date | What happens | Who should care |
|---|---|---|
| Aug 31, 2026 | Wegovy 4mg pill self-pay offer ends → $199/mo | Cash-pay pill users: a fill before the deadline locks one more month at $149 |
| Any week now | FDA final 503B determination could land | Anyone still using compounded semaglutide/tirzepatide — have your exit plan ready |
| Dec 31, 2026 | Wegovy & Ozempic pen intro offers ($199 first fills) end; Foundayo savings card expires | New starters and commercially insured Foundayo users |
| Dec 31, 2027 | Medicare GLP-1 Bridge program ends | Every Medicare member using the $50 benefit — this is temporary |
Get my cheapest path — $19/month
Next month's report, personalized to you, plus an alert the same week anything above changes. Cancel anytime.
References
- NovoCare/Wegovy cost page — wegovy.com/obesity/what-to-pay-for-wegovy.html (accessed July 12–13, 2026)
- Ozempic savings page — ozempic.com/savings-and-resources/save-on-ozempic.html (accessed July 12–13, 2026)
- Zepbound pricing — pricinginfo.lilly.com/zepbound (accessed July 12–13, 2026)
- Zepbound savings & refill terms — zepbound.lilly.com/savings (accessed July 12–13, 2026)
- Foundayo coverage & savings — foundayo.lilly.com/coverage-savings (accessed July 12–13, 2026)
- Foundayo pricing — pricinginfo.lilly.com/foundayo (accessed July 12–13, 2026)
- Medicare weight-loss drugs / GLP-1 Bridge — medicare.gov/coverage/weight-loss-drugs (accessed July 12–13, 2026)
- MassHealth GLP-1 coverage update — mass.gov/news/june-update-on-vida-health-program-and-glp-1-coverage (accessed July 12–13, 2026)
- GoodRx Wegovy — goodrx.com/wegovy (accessed July 12–13, 2026)
- GoodRx Zepbound — goodrx.com/zepbound (accessed July 12–13, 2026)
- KFF, Medicaid coverage of GLP-1s — kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/ (accessed July 12–13, 2026)
- FDA press announcement, proposed 503B exclusion — fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list (accessed July 12–13, 2026)
- Federal Register, Docket FDA-2018-N-3240 — govinfo.gov/content/pkg/FR-2026-05-01/html/2026-08552.htm (accessed July 12–13, 2026)
The GLP-1 Cost Tracker is an educational service from GLP-1 Answers, an independent health education resource. Nothing here is medical, legal, or insurance advice; medication decisions belong with you and your prescriber. Prices and coverage terms can change without notice — confirm directly with the program, plan, or pharmacy before making decisions. We take no money from manufacturers, pharmacies, insurers, or providers.